Quince Therapeutics Inc (QNCX)
Quince Therapeutics Inc. is a NASDAQ-listed common stock company focused on biopharmaceutical development for patients with debilitating and rare diseases. Its lead program is EryDex, which is being developed for rare pediatric neurodegenerative disorders, including ataxia-telangiectasia (A-T), a genetic condition linked to ATM gene mutations that causes both neurodegenerative and immunodeficiency symptoms. The company also develops the AIDE technology platform, a drug-device combination system designed to place a drug into a patient’s own red blood cells through an automated process. That platform includes the RCL automated equipment, a single-use sterile treatment kit, syringe kit, and process solutions. Founded in 2012 and headquartered in South San Francisco, California, the company was previously known as Cortexyme, Inc. and adopted its current name in August 2022.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-QNCX
|
$34.17
|
9.0% Upside
|
Fair
|
$75.43
|
140.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
31.885 M
|
59.359 M
|
0.0%
|
66.8%
|
-4.9
|
50.8%
|
